137 related articles for article (PubMed ID: 32130206)
1. Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance.
Craig SL; Gault VA; Hamscher G; Irwin N
J Endocrinol; 2020 May; 245(2):219-230. PubMed ID: 32130206
[TBL] [Abstract][Full Text] [Related]
2. The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin.
Craig SL; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2021 Jan; 183():114355. PubMed ID: 33279496
[TBL] [Abstract][Full Text] [Related]
3. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
4. A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice.
Craig SL; Perry RA; Vyavahare SS; Ng MT; Gault VA; Flatt PR; Irwin N
Biochem Pharmacol; 2020 Jan; 171():113723. PubMed ID: 31756326
[TBL] [Abstract][Full Text] [Related]
5. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
[TBL] [Abstract][Full Text] [Related]
7. Effects of an enzymatically stable C-terminal hexapseudopeptide fragment peptide of xenin-25, ψ-xenin-6, on pancreatic islet function and metabolism.
Craig SL; Gault VA; McClean S; Hamscher G; Irwin N
Mol Cell Endocrinol; 2019 Oct; 496():110523. PubMed ID: 31352038
[TBL] [Abstract][Full Text] [Related]
8. An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.
Hasib A; Ng MT; Gault VA; Khan D; Parthsarathy V; Flatt PR; Irwin N
Diabetologia; 2017 Mar; 60(3):541-552. PubMed ID: 28004148
[TBL] [Abstract][Full Text] [Related]
9. Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice.
Hasib A; Khan D; Craig SL; Gault VA; Flatt PR; Irwin N
Eur J Pharmacol; 2019 Dec; 865():172733. PubMed ID: 31614140
[TBL] [Abstract][Full Text] [Related]
10. Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.
Martin CM; Parthsarathy V; Hasib A; Ng MT; McClean S; Flatt PR; Gault VA; Irwin N
PLoS One; 2016; 11(3):e0152818. PubMed ID: 27032106
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of the biological activity of xenin-25 degradation fragment peptides.
Martin CM; Parthsarathy V; Pathak V; Gault VA; Flatt PR; Irwin N
J Endocrinol; 2014 May; 221(2):193-200. PubMed ID: 24520141
[TBL] [Abstract][Full Text] [Related]
12. Xenin-25[Lys13PAL]: a novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential.
Gault VA; Martin CM; Flatt PR; Parthsarathy V; Irwin N
Acta Diabetol; 2015 Jun; 52(3):461-71. PubMed ID: 25374384
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.
Tanday N; Flatt PR; Irwin N; Moffett RC
J Endocrinol; 2020 Apr; 245(1):53-64. PubMed ID: 31977315
[TBL] [Abstract][Full Text] [Related]
14. Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice.
McCloskey AG; Miskelly MG; Lafferty RA; Flatt PR; McKillop AM
Biochem Pharmacol; 2023 Feb; 208():115398. PubMed ID: 36581052
[TBL] [Abstract][Full Text] [Related]
15. Enzymatically stable analogue of the gut-derived peptide xenin on beta-cell transdifferentiation in high fat fed and insulin-deficient Ins1
Tanday N; Moffett RC; Gault VA; Flatt PR; Irwin N
Diabetes Metab Res Rev; 2021 Mar; 37(3):e3384. PubMed ID: 32662136
[TBL] [Abstract][Full Text] [Related]
16. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the degradation and metabolic effects of the gut peptide xenin on insulin secretion, glycaemic control and satiety.
Taylor AI; Irwin N; McKillop AM; Patterson S; Flatt PR; Gault VA
J Endocrinol; 2010 Oct; 207(1):87-93. PubMed ID: 20631047
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-acting GIP, xenin and oxyntomodulin peptide analogues on alpha-cell transdifferentiation in insulin-deficient diabetic Glu
Sarnobat D; Moffett RC; Gault VA; Tanday N; Reimann F; Gribble FM; Flatt PR; Irwin N
Peptides; 2020 Mar; 125():170205. PubMed ID: 31738969
[TBL] [Abstract][Full Text] [Related]
19. Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25.
Martin CM; Gault VA; McClean S; Flatt PR; Irwin N
Biochem Pharmacol; 2012 Aug; 84(3):312-9. PubMed ID: 22561048
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
